Home › Triple-Negative Breast Cancer › Indiana
Triple-Negative Breast Cancer clinical trials in Indiana
13 studies for Triple-Negative Breast Cancer are looking for participants at sites in Indiana.
Cities in Indiana
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Northwest Cancer Center - Dyer Clinic ( Site 0097), Dyer
- Parkview Research Center at Parkview Regional Medical Center ( Site 0011), Fort Wayne
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06393374A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Fort Wayne Medical Oncology and Hematology ( Site 0084), Fort Wayne
- Franciscan Health ( Site 0077), Indianapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Franciscan Health Indianapolis, Indianapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05633654A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- IU Simon Cancer Center, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06465069Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- IU Health Joe and Shelly Schwarz Cancer Center, Carmel
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT05846789Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Goshen Center for Cancer Care, Goshen
RecruitingObservational study
Ages 18 to 99 · All sexes · Updated Sep 3, 2026 · NCT07211178A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT06150664A Study of LY4175408 in Participants With Advanced Cancer
- Community Health Network, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT07046923Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne
- Community Health Network, Inc. /ID# 243011, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT05005403A Study of Tetrathiomolybdate (TM) Plus Capecitabine
- Indiana University Simon Cancer Center, Indianapolis
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Apr 20, 2026 · NCT06134375NearWave Optical Molecular Monitoring
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Recruiting
Ages 18 and older · Women · Updated Feb 17, 2026 · NCT06744465A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Community Health Network, Indianapolis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05902988A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Northwest Cancer Center, Dyer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 19, 2025 · NCT06568692From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.